Novo Nordisk affirms 25% weight-loss expectation for experimental drug CagriSema
Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its expectation the new injection will deliver 25% weight loss.
Novo Nordisk's Obesity Drug Quest: High Stakes and New Challenges
Novo Nordisk's experimental obesity drug CagriSema shows similar side effects to its GLP-1 drugs, with potential for 25% weight loss. Data from a late-stage trial is expected by end of 2024. The company's shares could rise or fall by 20% based on the trial's success.
Operating profit increased by 21% in Danish kroner and by 22% at constant exchange rates (CER) to DKK 91.6 billion.Sales in ...
Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...
Data on the subcutaneous version of amycretin is due next year, and Novo Nordisk also presented early data on another oral therapy, CBR1 inverse agonist monlunabant (INV-202), which showed a 3% ...
However, recent efficacy and side effect concerns over Novo Nordisk's pipeline candidate Monlunabant have likely worsened NVO's recent buying sentiments as investors reassessed future growth ...
Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.
Novo Nordisk ( (NVO) ) has released its Q3 earnings. Here is a breakdown of the information Novo Nordisk presented to its investors. Novo ...
Novo Nordisk (NYSE:NVO) (CSE:NOVOb) reported strong growth for the first nine months of 2024, with sales jumping by 23% in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback